Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5272043
Max Phase: Preclinical
Molecular Formula: C20H18N2O3
Molecular Weight: 334.38
Associated Items:
ID: ALA5272043
Max Phase: Preclinical
Molecular Formula: C20H18N2O3
Molecular Weight: 334.38
Associated Items:
Canonical SMILES: Cn1ccc(=O)c(O)c1C(=O)NCc1ccc(-c2ccccc2)cc1
Standard InChI: InChI=1S/C20H18N2O3/c1-22-12-11-17(23)19(24)18(22)20(25)21-13-14-7-9-16(10-8-14)15-5-3-2-4-6-15/h2-12,24H,13H2,1H3,(H,21,25)
Standard InChI Key: FSEDMHXJLQVYKB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 334.38 | Molecular Weight (Monoisotopic): 334.1317 | AlogP: 2.69 | #Rotatable Bonds: 4 |
Polar Surface Area: 71.33 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.52 | CX Basic pKa: | CX LogP: 2.83 | CX LogD: 2.83 |
Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.77 | Np Likeness Score: -0.67 |
1. Arshad JZ, Hanif M.. (2022) Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors., 13 (10.0): [PMID:36325396] [10.1039/d2md00175f] |
Source(1):